David Shaw’s POINT Biopharma Global Inc. Common Stock PNT Stock Holding History

David Shaw’s Portfolio PNT Stock Details PNT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-167,955	Closed	-$1.12M	–	4711
2023 Q3	$1.12M	Buy	167,955 +29,781	+22%	+$248K	﹤0.01%	2992
2023 Q2	$1.25M	Buy	+138,174	New	+$1.22M	﹤0.01%	2949
2022 Q2	–	Sell	-43,744	Closed	-$349K	–	5926
2022 Q1	$349K	Sell	43,744 -39,308	-47%	-$250K	﹤0.01%	4575
2021 Q4	$465K	Buy	83,052 +20,170	+32%	+$151K	﹤0.01%	4445
2021 Q3	$484K	Sell	62,882 -3,400	-5%	-$31K	﹤0.01%	4102
2021 Q2	$681K	Buy	+66,282	New	+$674K	﹤0.01%	3850

Other funds holding PNT

BTI

Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return

David Shaw's PNT Position: Q4 2023 in Review

David Shaw sold out of POINT Biopharma Global Inc. Common Stock (PNT) in Q4 2023, closing a stake of 167,955 shares — an estimated $1.12M sold.

David Shaw first reported a position in PNT in Q2 2021 and held it in 6 quarters. The position peaked at $1.25M in Q2 2023. 1 fund tracked by Wall St. Rank holds PNT as of Q4 2023.

David Shaw reported no remaining POINT Biopharma Global Inc. Common Stock position as of Q4 2023 after selling out during the quarter.
David Shaw sold 167,955 POINT Biopharma Global Inc. Common Stock shares in Q4 2023, an estimated $1.12M.
David Shaw first reported a position in POINT Biopharma Global Inc. Common Stock in Q2 2021 and held it in 6 quarters.
David Shaw's POINT Biopharma Global Inc. Common Stock position peaked at $1.25M in Q2 2023.
1 fund tracked by Wall St. Rank held POINT Biopharma Global Inc. Common Stock as of Q4 2023.

Based on D.E. Shaw & Co's 13F filing for Q4 2023, filed 14 Feb 2024.